Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Pacira BioSciences, Inc.

NASDAQ: PCRX · Life Sciences · 6 alerts · CIK 1396814

Share price
$36.48Close, Nov 16
Market cap
$1.46B
Shares outstanding
40.09MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pacira BioSciences, Inc. filings on SEC EDGAR ↗

9:43 AM ET 8-K
M&A Deal

Pacira BioSciences M&A Deal with Viatris Inc.

Pacira BioSciences, Inc. completed its merger with Viatris Inc. on November 17, 2026, following a tender offer where Viatris acquired all outstanding shares for $36.50 per share in cash. As a result of the transaction, Pacira has become a wholly owned subsidiary of Viatris and entered into supplemental indentures to address its outstanding 2.125% Convertible Senior Notes due 2029.

Counterparty
Viatris Inc.
4:21 PM ET 8-K
Court & Legal Update

Pacira BioSciences Court & Legal Update

The U.S. Court of Appeals for the Ninth Circuit partially reversed a lower court ruling, determining that Pacira BioSciences owes royalties to the Research Development Foundation (RDF) for EXPAREL manufactured using its 200-liter process. This decision impacts a previous $28.3 million recovery Pacira received and remands the case to the District Court to recalculate interest owed on other portions of the judgment.

Counterparty
Research Development Foundation
4:38 PM ET 10-Q
Financial Results

Pacira BioSciences Q3 2026 Results: Net Income $28.5M, Up 425.1% YoY

Pacira BioSciences reported a significant increase in net income to $28.5 million for Q3 2026, compared to $5.4 million in Q3 2025, despite a slight decrease in total revenues to $176.7 million. The company's financial position remains stable with $1.2 billion in total assets and a reduction in long-term debt to $293.6 million.

Key figure
Net income $28.5M · +425.1% YoY
4:34 PM ET 8-K
M&A Deal

Pacira BioSciences M&A Deal with Viatris Inc.

Pacira BioSciences provided a status update on its pending acquisition by Viatris Inc., noting that the tender offer for $36.50 per share commenced on October 30, 2026. Due to the pending merger, the company will not release Q3 2026 earnings or hold a conference call, and it has withdrawn its previously issued 2026 financial guidance.

Counterparty
Viatris Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.